Whitehawk Therapeutics, Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Whitehawk Therapeutics is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $3.25, 36.3% below its 52-week high and below its 200-day average, which is rising.

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. More about the company

$3.25

-1.07% today

$185M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is WHWK early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 32w

S4 17w

S2 20w

S2 38w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 32w → S1 7w → S4 17w → S1 5w → S2 20w → S3 5w → S4 9w → S1 8w → S4 7w → S1 3w → S2 38w → S3 5w → S2 6w → S3 2w current

Total tracked: 165 weeks across 14 stage runs.

WHWK among Biotechnology104th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…104	WHWKWhitehawk Therapeutics, Inc.	Stage 3 · wk 3	83	−14.9%

vs 52W High

-36.3%

$1.99 lo$5.10 hi

36.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-14.9%

200 DMA: $3.82 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.81x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.9%

-12.4%

-22.1%

YTD

+33.2%

+42.5%

Scan Membership

Breakout Watch

Latest: 2024-10-21

7 appearances in last 60 days. First seen: 2019-03-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 0.81x

2026-10-21S3

Wk 3 · Vol 0.75x

2026-10-20S3

Wk 3 · Vol 1.22x

2026-10-19S3

Wk 2 · Vol 1.51x

2026-10-16S3

Wk 2 · Vol 0.80x

2026-10-15S3

Wk 2 · Vol 0.96x

2026-10-14S3

Wk 2 · Vol 1.46x

2026-10-13S3

Wk 2 · Vol 1.33x

2026-10-12S3

Wk 1 · Vol 0.64x

2026-10-09S3

Wk 1 · Vol 0.92x

2026-10-08S3

Wk 1 · Vol 0.70x

2026-10-07S3

Wk 1 · Vol 1.22x

Moving averages & range

50 DMA

$4.03

200 DMA

$3.82

52W High

$5.10

52W Low

$1.99

5D Low

$2.89

Resistance levels (recent highs)

20d High

$3.76

60d High

$5.08

120d High

$5.10

250d High

$5.10

Next resistance

+15.7%

to 20d High

ROE

-45.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Whitehawk Therapeutics: quick answers

What stage is Whitehawk Therapeutics in?

As of Oct 22, 2026, Whitehawk Therapeutics (WHWK) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Whitehawk Therapeutics in an uptrend?

Its uptrend has stalled. Whitehawk Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 14.9% below its 200-day average, which is rising.

How far is Whitehawk Therapeutics from its 52-week high?

Whitehawk Therapeutics closed at $3.25 on Oct 22, 2026, 36.3% below its 52-week high of $5.10. Its 52-week low is $1.99.

How has Whitehawk Therapeutics performed over the past year?

As of Oct 22, 2026, Whitehawk Therapeutics is up 42.5% over the past year and up 33.2% so far in 2026.

Which sector and industry is Whitehawk Therapeutics in?

Whitehawk Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.